Non-Hodgkin Lymphoma

Criteria to qualify for study: Drug used in study:
  • Relapsed / Refractory
  • 2 part, multicenter, open label, phase 1a/1b study of TTI-622 in patients with advanced relapsed or refractory lymphoma and multiple myeloma

HR 56 TTI-622-01

A Phase 1a/1b dose escalation and expansion trial of TTI-622 in patients with Advanced Relapsed or Refractory Lymphoma or Myeloma.

HR 56 TTI-622-01 Clinical Trial

Criteria to qualify for study: Drug used in study:
  • Relapsed or refractory multiple myeloma or relapsed NHL; received at least 2 prior lines of therapy

HR 68

A phase I/II open label multi-center study to characterize the safety and tolerability of CFT7455 in subjects with relapsed/refractory Non-Hodgkin Lymphoma or Multiple Myeloma.

HR 68 Clinical Trial

Criteria to qualify for study: Drug used in study:
  • ECOG <1; relapsed or refractory NHL, ALL, or i NHL; at least 2 prior lines

HR 69

A phase 1 study of NKX019, a CD19 Chimeric Antigen Receptor Natural Killer (CAR NK) Cell therapy, in subjects with B-Cell Malignancies.

HR 69 Clinical Trial

Criteria to qualify for study: Drug used in study:
  • 1 Measurable lesion; Platelet count > 75,000/ul

LYM 111

Study to evaluate the efficacy of Brexucabtagene Autoleucel (KTE-X19) in participants with relapsed/refractory Mantle Cell Lymphoma (zuma-2)

LYM 111 Clinical Trial

Criteria to qualify for study: Drug used in study:
  • Eligible for first BMT after induction chemotherapy; archival tumor block for MRD testing.

LYM 155

Single arm, Phase II study of Acalabrutinib as post-Autologous Blood or Marrow Transplant (BMT) maintenance therapy in subjects with Mantel Cell Lymphoma.

LYM 155 Clinical Trial

Criteria to qualify for study: Drug used in study:
  • FL, MZL, SLL, DLBCL, HGBCL, PMBCL, MCL, or CLL; ECOG 0 or 1

LYM 166

Safety and efficacy of GEN3009 (DuoHexaBody-CD37) in relapsed or refractory B-cell Non-Hodgkin Lymphoma – A first in human, Open label, Phase 1/lla dose escalation trial with dose expansion cohorts.

LMY 166 Clinical Trial

Criteria to qualify for study: Drug used in study:
  • On HOLD
  • Relapsed/refractory Large B-cell Lymphoma; at least 1 measurable lesion; at least 2 lines of prior therapies including an anthracycline and an anti-CD20 monoclonal antibody

LYM 168

A Single-Arm, Open-Label, Phase 1/2 study evaluating the safety, efficacy and Cellular Kinetics/Pharmacodynamics of ALLO-501A, an Anti-CD19 Allogeneic CAR-T Cell Therapy in subjects with Relapsed/Refractory Large B-Cell Lymphoma (LBCL)

LMY 168 Clinical Trial

Criteria to qualify for study: Drug used in study:
  • CD20+; relapsed of refractory following anti – CD20 monoclonal antibody

LYM 171

A Phase 1/2, open label, dose escalation trial of GEN3013 in patients with relapsed, progressive or refractory B Cell Lymphoma.

LMY 171 Clinical Trial

Criteria to qualify for study: Drug used in study:
  • R/R CLL, SLL, WM, MCL, MZL, FL or DLBCL; ECOG 0 or 1

LYM 184

A Phase 1 dose escalation, safety and tolerability study of NX-2127, a Bruton’s Tyrosine Kinase (BTK) degrader, in adults with relapsed/refractory B-Cell malignancies.

LMY 184 Clinical Trial

Criteria to qualify for study: Drug used in study:
  • R/R T-Cell Lymphoma with at least 2 lines of prior therapy; CD5-expression tumor by IHC or flow cytometry

LYM 194

A Phase 1/2, open-label, first in human, multiple ascending dose multicenter study of MT-101 in subjects with CD5+ relapsed/refractory peripheral T Cell Lymphoma.

LYM 194 Clinical Trial
Criteria to qualify for study: Drug used in study:
  • R/R B-cell NHL after auto transplant or at least 2 prior lines including an anti-CD20 monoclonal antibody and an anthracycline containing chemotherapy regimen.

LYM 197

A Phase 1/2 study of bbT369, a dual targeting CAR-T cell drug product with a gene edit, in relapsed and/or refractory B Cell Non-Hodgkin Lymphoma.

LYM 197 Clinical Trial
Criteria to qualify for study: Drug used in study:
  • CD20+NHL; disease progression following 2 or more prior lines including a CD20 targeted therapy

LYM 198

Phase 1/2, Multicenter, first in human, dose-escalating study of CP0107 administered IVI to patients with incurable CD20+ve NHL.

LYM 198 Clinical Trial